Overview and Outlook for RNA-Based Therapies

This document is a comprehensive report on RNA-based therapies, detailing their development, classification, and regulatory landscape. RNA-based therapies represent a novel approach to treating various diseases, including rare conditions, by utilizing genetically targeted technology. The report outlines the different categories of RNA-based therapies, including RNA interference (RNAi), antisense oligonucleotides (ASOs), and messenger RNA (mRNA) therapies. It highlights the current FDA-approved RNA therapies and discusses the ongoing clinical trials, emphasizing the potential for new treatment options. The document also explains the FDA's regulatory classifications for these therapies, noting the distinctions between small molecule drugs and biological drugs. Furthermore, it addresses the implications of policies such as the Inflation Reduction Act on RNA-based therapies and their market dynamics. The report concludes with an outlook on the future of RNA-based therapies, encouraging stakeholders to consider the evolving regulatory environment and its impact on product development and patient access.